Biomarker Card
This biomarker card gives comprehensive information about each biomarker.
| Detailed Information | |
|---|---|
| Biomarker ID | 1888 |
| PMID | 30853355 |
| Year | 2019 |
| Biomarker | 4-(3,4-dihydro-2,2,4-trimethyl-2H-1-benzopyran-4-yl)-phenol; Estradiol; Ethyl à-hydroxymyristate trisiloxane; 1-(2,4-Dimethylphenyl)-3-(tetrahydrofuryl-2)propane; 2-amino-Imidazole-5-carboxylic acid; 1,1,3,3,5,5,7,7,9,9-decamethyl-pentasiloxane; 1,1,1,5,5,5-hexamethyl-3,3-bis[(trimethylsilyl)oxy]-Trisiloxane; Phthalic acid, bis(7-methyloctyl) ester; 4-Nitro-4’-chlorodiphenylsulfoxide; 1-Propylpentachlorotriphosphazene; 2,6-di-t-butyl-4-hydroxymethylene-2,3,5,6-detetrahydrocyclohexanone |
| Biomarker Basis | Concentration Based |
| Biomolecule | Metabolites |
| Source | Urine |
| Subjects | Humans |
| Regulation | Downregulated in PCa [SCOâ€spondin (0.1 fold); Complement component C7 (0.1â€fold); Isoform 2 of Ankyrin repeat and SOCS box protein 18 (0.3â€fold); Gelsolin (0.3â€fold); Serum amyloid P-component (0.4â€fold); Ig heavy chain Vâ€I region V35 (0.5â€fold); Complement C1q subcomponent subunit C (0.5â€fold); Complement component C8 alpha chain (0.6â€fold); Isoform 2 of Filamin A (0.6â€fold); and Inter-alpha-trypsin inhibitor heavy chain H2 (0.7â€fold);] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Prostate Cancer Vs No Prostate Cancer |
| Type of Biomarker | Diagnostic |
| Cohort | 108 patients (55 PCa-positive and 53 PCa controls) were selected for training model. And 53 with PCa and 22 controls were selected for validation |
| Senstivity | NA |
| Specificity | Training: 0.80; Testing: 0.77 |
| AUC | Training: 0.92 (95% CI: 0.865-0.975); Testing: 0.863 (95% CI: 0.779; 0.947) |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | Gas chromatography–mass spectrometry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |